Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00371150
Other study ID # AI463-085
Secondary ID
Status Completed
Phase Phase 4
First received August 29, 2006
Last updated March 22, 2012
Start date November 2006
Est. completion date March 2011

Study information

Verified date March 2012
Source Bristol-Myers Squibb
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this clinical research study is to develop observational clinical experience with the use of entecavir in participants who are either of Black/African-American race or of Hispanic ethnicity.


Recruitment information / eligibility

Status Completed
Enrollment 131
Est. completion date March 2011
Est. primary completion date March 2011
Accepts healthy volunteers No
Gender Both
Age group 16 Years and older
Eligibility Inclusion Criteria:

- Chronic HBV infection, with either HBeAg-positive (HBeAb-negative) or HBeAg-negative (HBeAb-positive) disease

- Black/African American Race and/or Hispanic ethnicity

- Nucleoside/tide-naive

- Males or females = 16 years of age (or minimum age required in a given country)

- Compensated liver function

- ALT of 1.3 to 10 x upper limit of normal (ULN)

- No Co-infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV) or hepatitis D virus (HDV)

Exclusion Criteria

- Women of childbearing potential (WOCBP) who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 6 weeks after study medication has been discontinued

- Women who are pregnant or breastfeeding

- Women with a positive pregnancy test on enrollment or prior to study drug administration

- Evidence of decompensated cirrhosis including but not limited to: variceal bleeding; hepatic encephalopathy; or ascites requiring management with diuretics or paracentesis

- Recent history of pancreatitis (resolution of any recent pancreatitis must be documented by normal lipase at least 12 weeks prior to the first dose of study medication)

- Currently abusing illegal drugs or alcohol sufficient, in the investigator's opinion, to prevent adequate compliance with study therapy or to increase the risk of hepatotoxicity or pancreatitis

- Other serious medical conditions that might preclude completion of this study or that require chronic administration of prohibited medications

- Serum creatinine > 1.5 mg/dL

- Hemoglobin < 10.0 g/dL

- Platelet count < 70,000/mm3

- Absolute neutrophil count < 1200 cells/mm3

- Serum alpha fetoprotein (AFP) level > 100 ng/mL. If the AFP level is between 21 and 100 ng/mL, it must be repeated. If the repeat AFP level is between 21 and 100 ng/mL and if ultrasonography or computerized tomography (CT) of the liver performed prior to the first dose of study medication does not demonstrate a focal lesion suggestive of carcinoma, the subject may be dosed in the study

- Known history of allergy to nucleoside analogues

- Any prior therapy with Entecavir

- Any prior or concomitant use of nucleoside or nucleotide analogue antiviral agents with activity against hepatitis B (e.g., ETV, lamivudine (LVD), tenofovir [TDF], emtricitabine (FTC), clevudine, telbivudine [LdT], famciclovir), or any other experimental anti-HBV antiviral agent

- Therapy with interferon, thymosin alpha or other immunostimulators within 24 weeks of enrollment (i.e., dosing) into this study

- Subjects who require chronic administration of concomitant medications which cause immunosuppression or which are associated with a high rate of nephrotoxicity or hepatotoxicity, or which affect renal excretion, should not be enrolled in this study

- Unable to tolerate oral medication

- Poor peripheral venous access

- Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious disease) illness must not be enrolled into this study

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
Entecavir
Tablets, Oral, 0.5 mg, once daily, up to 52 weeks

Locations

Country Name City State
Brazil Local Institution Belo Horizonte - Mg Minas Gerais
Brazil Local Institution Campinas Sao Paulo
Brazil Local Institution Rio De Janeiro - Rj Rio De Janeiro
Brazil Local Institution Salvador Bahia
Brazil Local Institution Sao Paulo - Sp Sao Paulo
Mexico Local Institution Df Distrito Federal
Mexico Local Institution Guadalajara Jalisco
Mexico Local Institution Guadalajara Jalisco
Mexico Local Institution Guadalajara Jalisco
Mexico Local Institution Zapopan Jalisco
Puerto Rico Local Institution Santurce
South Africa Local Institution Belville Western Cape
South Africa Local Institution Goodwood Western Cape
United States Brigham And Women'S Hospital Boston Massachusetts
United States University Of Chicago Chicago Illinois
United States Banks Hepatology Institute, Pc College Park Maryland
United States Empire International Research Miami Florida
United States University Of Miami Miami Florida
United States Alabama Liver & Digestive Specialists (Alds) Montgomery Alabama
United States Va New York Harbor Healthcare System New York New York
United States Albert Einstein Healthcare Network Philadelphia Pennsylvania
United States Hunter Holmes Mcguire D V A M C Richmond Virginia
United States Alamo Medical Research San Antonio Texas
United States L L C Bda The Research Institute Springfield Massachusetts
United States University Of Arizona Tucson Arizona
United States George Washington University Medical Center Washington District of Columbia
United States Westchester Digestive Disease Group, Llp Yonkers New York

Sponsors (1)

Lead Sponsor Collaborator
Bristol-Myers Squibb

Countries where clinical trial is conducted

United States,  Brazil,  Mexico,  Puerto Rico,  South Africa, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants With HBV Deoxyribonucleic Acid (DNA) < 50 IU/mL by Polymerase Chain Reaction (PCR) at Week 48 HBV DNA assessments were performed using the Roche COBAS® TaqMan AmpliPrep assay. HBV DNA < 50 IU/mL = approximately <300 copies/mL. Week 48 of ETV treatment No
Secondary Percentage of Participants Who Achieve HBV DNA < Lower Limit of Quantitation (LOQ = 29 IU/mL [Approximately 169 Copies/mL]) at Week 48 HBV DNA assessments were performed using the Roche COBAS® TaqMan AmpliPrep assay. LOQ is the level above which quantitative results may be obtained with a specified degree of confidence. The LOQ is mathematically defined as equal to 10 times the standard deviation of the results for a series of replicates used to determine a justifiable limit of detection. Week 48 No
Secondary Percentage of Participants With HBV DNA by PCR Category at Week 48 HBV DNA assessments were performed using the Roche COBAS® TaqMan AmpliPrep assay. Week 48 No
Secondary Percentage of Participants With Virologic Rebound Through Week 48 While on Continued Dosing With ETV Virologic rebound is defined as a confirmed increase of = 1 log10 in HBV DNA from the participant's nadir value (2 sequential HBV DNA measurements or last on-treatment measurement) through Week 48 No
Secondary Percentage of Participants With Alanine Aminotransferase (ALT) Normalization at Week 48 ALT normalization=ALT level being less than or equal to 1 times the upper limit of normal (ULN). ULN for ALT is 37 U/L. Week 48 No
Secondary Percentage of Participants With Confirmed HBeAg Loss at Week 48 (for HBeAg-positive Participants Only) HBeAg is a hepatitis B viral protein. HBeAg loss = HBeAg-negative at the specified analysis week Week 48 No
Secondary Percentage of Participants With HBeAg Seroconversion at Week 48 (for HBeAg-positive Participants Only) HBeAg is a hepatitis B viral protein. HBeAg Seroconversion = HBeAg Loss and Presence of Hepatitis B e Antibody (HBeAb). Week 48 No
Secondary Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Week 48 HBsAg = a part of the hepatitis B virus that, when in the blood, is a marker of infection. HBsAg loss = HBsAg-negative at the specified analysis week. Week 48 No
Secondary Percentage of Participants With HBsAg Seroconversion at Week 48 HBsAg = a part of the hepatitis B virus that, when in the blood, is a of infection. HBs seroconversion is defined as HBsAg loss with positive HBsAb. Week 48 No
Secondary Mean log10 Reduction From Baseline in HBV DNA at Week 48 HBV DNA was analyzed by PCR, using the Roche COBAS®TaqMan TaqMan AmpliPrep assay. Reduction in log10 HBV count=reduced viral load. baseline, Week 48 No
Secondary Percentage of Participants With HBV DNA < Other IU Cut-off Points That May be Clinically Relevant at the Time of Data Analysis Week 48 No
Secondary Number of Participants With Adverse Events (AE), Serious Adverse Events (SAE), and Discontinuations From Study Drug Due to Adverse Events AE: any new untoward medical occurrence/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Participants who discontinued the study due to any AEs were recorded. From enrollment through Week 52 + 5 days Yes
Secondary Number of Participants With Laboratory Abnormalities On-treatment (OT) and Off-Treatment (OF): Hematology Criteria for hematology abnormalities were graded using the modified WHO grading system. Hemoglobin: <=11.0 g/dL; White Blood Cells: <4000/mm^3; Absolute Neutrophils (includes absolute bands): <1500/mm^3; Platelets: <=99,000/mm^3; International Normalized Ratio: = 1.5 and = 0.5 from baseline. OT: From start of study therapy through Week 52 + 5 days; OF= End of OT period + 24-week follow-up Yes
Secondary Number of Participants With Laboratory Abnormalities On-treatment (OT) and Off-Treatment (OF) : Serum Chemistry The modified World Health Oranization(WHO)grading system was used to grade the abnormalities. ULN=upper limit of normal. Alanine aminotransferase:>1.25xULN, Aspartate aminotransferase:>1.25xULN, Alkaline Phosphatase:>1.25xULN, Total Bilirubin:>1.1xULN, Serum Lipase:>1.10xULN, Creatinine:>1.1xULN, Blood Urea Nitrogen:1.25xULN, Hyperglycemia:>116 mg/dL, Hypoglycemia:<64 mg/dL, Hyponatremia:<132meq/L, Hypokalemia:<3.4 meq/L, Albumin:=1g/dL decrease from baseline, <3 g/dL; Hypernatremia:>148 meq/L, Hyperkalemia:>5.6 meq/L, Hypokalemia:<3.4 meq/L, Hyperchloremia:>113 meq/L, Hypochloremia:<93 meq/L OT: From start of study therapy through Week 52 + 5 days; OF= End of OT period + 24-week follow-up Yes
See also
  Status Clinical Trial Phase
Recruiting NCT04704024 - Reducing Vertical Transmission of Hepatitis B in Africa Phase 3
Active, not recruiting NCT02143401 - Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors Phase 1
Active, not recruiting NCT03519113 - HBV-associated Liver Transplant(LT) Patients by IV Injecting GC1102 Phase 2/Phase 3
Completed NCT01788371 - Nucleoside Analogue Prevent Vertical Transmission of Hepatitis B Virus Phase 4
Recruiting NCT06368479 - Diagnostic Sensitivity and Specificity of iStatis HBsAg Test at the Point-Of-Care Site Settings N/A
Completed NCT01488526 - Tenofovir in Late Pregnancy to Prevent Vertical Transmission of Hepatitis B Virus Phase 4
Terminated NCT02826018 - A Study of ALN-HBV in Healthy Adult Volunteers and Non-cirrhotic Patients With Chronic Hepatitis B Virus (HBV) Infection Phase 1
Completed NCT01970254 - Widespread vs. Selective Screening for Hepatitis B Infection Prior to Chemotherapy
Completed NCT00489099 - A Research Study to Test Safety, Tolerability, and Immunogenicity of a Recombinant Hepatitis B Vaccine Manufactured With an Upgrade to the Production Process (V232-054) Phase 3
Recruiting NCT03476083 - Tenofovir Disoproxil Fumarate in Combination of Hepatitis B Vaccine for Preventing Hepatitis B Vertical Transmission Phase 4
Recruiting NCT03865966 - Hepatitis B Virus Infection After Liver Transplantation in Children
Completed NCT03627507 - Non Inferiority Trial of Locally Manufactured 'Hepa-B' Vaccine in Bangladesh. Phase 2/Phase 3
Completed NCT02443233 - Evaluation of Paternal, Maternal and Obstetric Factors Leading to the Hepatitis B Immunization Failure in Hong Kong N/A
Completed NCT00841477 - An Hepatitis B Vaccine Model for HIV Vaccine Trials in Drug Users Phase 3
Terminated NCT03887702 - Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors Phase 3
Completed NCT02304315 - A Phase 2 Study of GC1102 (Recombinant Hepatitis B Immunoglobulin) in HBV-related Liver Transplant Recipients Phase 2
Active, not recruiting NCT05117541 - Social-environmental, Psychosocial, Behavioral, Clinical and Biological Drivers of Disparities in Liver Disease Progression Among Korean American With Chronic Hepatitis B Infection
Not yet recruiting NCT06368466 - A Study to Evaluate Diagnostic Sensitivity and Specificity of iStatis HBsAg Test at the Point-Of-Care Sites N/A